The biotech company has signed an agreement with the company Nobera Pharma for the development of a new drug aimed at treating palmar plantar (hand-foot syndrome).
The palmar plantar is a common side effect in cancer patients treated with certain chemotherapies as capacetabina and other fluoropyrimidines. Following the initiation of chemotherapy a high percentage of patients develop a skin reaction where there is redness in the palms and soles of the feet, accompanied by other symptoms such as tingling, peeling and blistering.
Around 18,000 patients in Spain suffer from this side effect, affecting the quality of life and often have to reduce or even discontinue chemotherapy. There is currently no treatment for this indication, so that the development of this new medicine would solve a major problem in oncology.
Advancell, a leading biotechnology company cell research into methods for in vitro research and innovative therapeutic strategies to treat nanomedicine as unmet needs in health and wellness, has signed an agreement with the company Nobera Pharma SL development of a drug intended to treat an important side effect that occurs in cancer patients, the plantar palmar, also known as hand-foot syndrome.
The palmar plantar skin reaction to chemotherapy, relatively common, seen in erythema (redness) pain localized to the palms and soles. In general, is accompanied by paresthesias (tingling and numbness sensations) with appearance, as they aggravate the syndrome, peeling, blistering, ulceration and severe pain, leading to interfere with basic functions like walking or grasping objects. In more severe cases, is the main cause of dose reduction or discontinuation of chemotherapy.
Through this agreement, the Spanish biotechnology, located in the Barcelona Science Park and has research centers in Barcelona, Valencia and Santiago de Compostela, initiate the development of this drug, which was originally discovered and patented by Nobera Pharma SL, a company with a vocation to promote and develop innovations that originate in daily clinical oncology practice, in direct contact with patients.
There is currently no effective treatment for palmar plantar, whose mechanism of action is not clearly known. Treatment and prevention of this side effect would solve a major problem in oncology. It is especially common in patients treated with capacetabina and other fluoropyrimidines such as 5-fluorouracil, used to treat breast cancer and colorectal cancer and other cancers such as gastric or pancreatic. The incidence is about 50% of patients treated with capacetabina, ranging between 10 and 70% in patients treated with other fluoropyrimidines.
In Spain, about 18,000 patients suffer from this side effect. Specifically, about 40% of patients who develop plantar palmar forced to reduce the dose of treatment, and it is estimated that approximately 15% include breaking. Reduction or discontinuation of chemotherapy significantly reduces the chances of survival of these patients.
The drug's development is currently in preclinical phase and it is estimated that during the first quarter of 2010 was initiated clinical studies. The main objective of this development is that, with medication, patients can get to complete their planned chemotherapy as scheduled, in addition to substantially improving the quality of life of patients during treatment.
According to oncologists, the drug would solve a major problem for patients under said chemotherapy, for which there is today an effective solution.
About Advancell (www.advancell.net)
Advancell is a biotechnology company with proprietary technology and continuous innovation, is unmet needs in health and wellness products and efficient services and value added. The company draws on findings of the academic environment to improve, develop and exploit the market.
The company has three divisions: Advancell Therapeutics, which focuses on development to clinical proof of concept of innovative drugs by finding new applications for molecules already known Advancell Alternative Testing, that uses cell-based in vitro to predict the efficacy, safety and mechanism of action of molecules in development and Nanosystems Advancell, using nanomedicine, treat and prevent disease.
The business model Advancell you can significantly reduce costs, risks and time of drug development. Its projects in clinical stage nanomedicine focus on the treatment of psoriasis (in collaboration with ISDIN) and the development of a new orphan drug for Chronic Lymphocytic Leukemia (in collaboration with the British Protherics). Moreover, cellular reagents ready for use developed by Alternative Testing Advancell a position of European leadership in its class.
The company is located in the Barcelona Science Park and has research centers at the University of Santiago de Compostela and Hospital La Fe in Valencia.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment